ALMIRALL news, videos and press releases
For more news please use our advanced search feature.
ALMIRALL - More news...
ALMIRALL - More news...
- Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
- Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
- Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
- Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing
- Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase
- Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase
- Almirall’s First Quarter 2023 Results
- Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
- Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) Publish Ph3 Data Evaluating lebrikizumab Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis
- Almirall’s Full-Year 2022 Results
- Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
- Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
- Almirall’s Nine-month 2022 Results
- Almirall opens a new subsidiary for the Czech Republic and Slovakia
- Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis
- Almirall PROSES study demonstrates appropriate acne treatment decreases the burden of impact on acne sufferers’ social and emotional wellbeing
- Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
- Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc
- Almirall: Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis
- Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
- Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
- Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials
- Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
- Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
- Almirall: Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
- Almirall: Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies
- Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall
- Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall
- Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers
- Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers
